Aspen Pharmacare Debt to Equity Ratio 2017-2025 | APNHY
Current and historical debt to equity ratio values for Aspen Pharmacare (APNHY) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Aspen Pharmacare debt/equity for the three months ending December 31, 2025 was 0.00.
| Aspen Pharmacare Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2025-12-31 | $2.74B | $4.74B | 0.58 |
| 2025-06-30 | $2.81B | $4.68B | 0.60 |
| 2024-12-31 | $2.87B | $4.75B | 0.61 |
| 2024-06-30 | $2.91B | $4.54B | 0.64 |
| 2023-12-31 | $2.87B | $4.57B | 0.63 |
| 2023-06-30 | $2.71B | $4.86B | 0.56 |
| 2022-12-31 | $2.58B | $4.27B | 0.60 |
| 2022-06-30 | $2.66B | $4.67B | 0.57 |
| 2021-12-31 | $2.95B | $4.68B | 0.63 |
| 2021-06-30 | $2.87B | $4.28B | 0.67 |
| 2020-12-31 | $3.71B | $4.26B | 0.87 |
| 2020-06-30 | $4.12B | $4.46B | 0.92 |
| 2019-06-30 | $4.80B | $3.82B | 1.26 |
| 2018-12-31 | $5.77B | $3.66B | 1.58 |
| 2018-06-30 | $6.46B | $3.91B | 1.65 |
| 2017-12-31 | $5.75B | $3.26B | 1.77 |
| 2017-06-30 | $5.38B | $3.17B | 1.70 |
| 2016-12-31 | $4.92B | $2.84B | 1.73 |
| 2016-06-30 | $4.29B | $2.95B | 1.45 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $3.708B | $2.388B |
| Aspen Pharmacare Holdings Limited provide specialty, branded and generic pharmaceuticals for acute and chronic conditions. It operates primarily in Sub-Saharan Africa, Latin America, South East Asia and Eastern Europe. Aspen Pharmacare Holdings Limited is headquartered in Durban, South Africa. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |